ESC Premium Access

Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study

Congress Presentation

About the speaker

Professor Shizuya Yamashita

Rinku General Medical Center, Izumisano (Japan)
0 follower

5 more presentations in this session

A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C

Speaker: Doctor S. Shah (Rahway, US)

Thumbnail

Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate

Speaker: Doctor M. Blazing (Durham, US)

Thumbnail

Clinical tolerability and safety profile of CER-001, a novel bio-engineered pre-beta HDL-mimetic, across the clinical development programs

Speaker: Professor A. Corsini (Milan, IT)

Thumbnail

Effect of pcsk9 antibodies on neurocognitive outcomes and improved survival in patients at higher risk: a meta-analysis of randomised controlled trials

Speaker: Doctor M. Kolodziejczak (Bydgoszcz, PL)

Thumbnail

Dose-response relationship between proton pump inhibitor use and associated risk of myocardial infarction: a nationwide cohort study

Speaker: Doctor T. Sehested (Copenhagen, DK)

Thumbnail

Access the full session

Lipid-lowering agents - New perspectives

Speakers: Professor S. Yamashita, Doctor S. Shah, Doctor M. Blazing, Professor A. Corsini, Doctor M. Kolodziejczak...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb